酸甲酸环酶刺激剂提供者guat:基于FAERS的药监测研究的见解和不良事件
International journal of clinical pharmacology and therapeutics
|December 30, 2025
概括
一种心力衰竭药物Vericiguat在一项大型安全性分析中显示了低血压和头等常见副作用. 还发现了新的不良事件,包括胃肠道出血和功能障碍.
科学领域:
- 药物监督 药物监督 药物监督
- 心血管医学 心血管医学
- 药品安全 药品安全
背景情况:
- 维里西瓜特是一种可溶性瓜尼酸环酶刺激剂,越来越多地用于心力衰竭和减少射出分数的治疗.
- 有限的长期安全数据存在于广大群体的输送者guat.
研究的目的:
- 通过使用市场后不良事件数据来评估 vericiguat 的安全性.
- 为了识别与输送器治疗相关的已知和新出现的不良事件.
主要方法:
- 美国食品和药物管理局不良事件报告系统 (FAERS) 数据库的回顾性分析.
- 使用了四种算法:多项性马鱼缩小器,贝叶斯式信任传播神经网络,比例报告比率和报告几率比率.
- 在首选术语级别分析了不良事件信号.
主要成果:
- 从886份报告中确定了1863个不良事件,其中输送器是主要嫌疑人.
- 在64个首选术语中检测到853个信号.
- 常见的不良事件包括低血压,头,消化不良和贫血,与临床试验一致.
- 确定了新的不良事件,如胃肠道出血和功能障碍.
结论:
- 这项研究提供了一个全面的安全评估的 vericiguat.
- 这些发现与之前的临床试验数据大致一致.
- 鉴定出新的不良事件需要进一步调查,并为临床实践提供信息.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.7K
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
7.3K
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Therapeutic Drug Monitoring: Affecting Factors
163
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
163
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
GPCRs Regulate Adenylyl Cylase Activity
7.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.2K
Therapeutic Drug Monitoring: Overview and Classification
257
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
257
Antiepileptic Drugs: Potassium Channel Activators
586
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
586
